Search Results - "Bockmann, Jan Hendrik"

Refine Results
  1. 1
  2. 2

    Defining the CD39/CD73 Axis in SARS-CoV-2 Infection: The CD73 - Phenotype Identifies Polyfunctional Cytotoxic Lymphocytes by Ahmadi, Parimah, Hartjen, Philip, Kohsar, Matin, Kummer, Silke, Schmiedel, Stefan, Bockmann, Jan-Hendrik, Fathi, Anahita, Huber, Samuel, Haag, Friedrich, Schulze Zur Wiesch, Julian

    Published in Cells (Basel, Switzerland) (22-07-2020)
    “…The ectonucleotidases CD39 and CD73 regulate immune responses by balancing extracellular ATP and adenosine in inflammation and are likely to be involved in the…”
    Get full text
    Journal Article
  3. 3
  4. 4
  5. 5

    Combined glucocorticoid and antiviral therapy of hepatitis B virus-related liver failure by Bockmann, Jan-Hendrik, Dandri, Maura, Lüth, Stefan, Pannicke, Nadine, Lohse, Ansgar W

    Published in World journal of gastroenterology : WJG (21-02-2015)
    “…Acute hepatic failure due to hepatitis B virus(HBV)can occur both during primary infection as well as after reactivation of chronic infection.Guidelines…”
    Get full text
    Journal Article
  6. 6
  7. 7

    Clinical establishment of a laboratory developed quantitative HDV PCR assay on the cobas6800 high-throughput system by Pflüger, Lisa Sophie, Nörz, Dominik, Volz, Tassilo, Giersch, Katja, Giese, Annika, Goldmann, Nora, Glebe, Dieter, Bockmann, Jan-Hendrik, Pfefferle, Susanne, Dandri, Maura, Schulze zur Wiesch, Julian, Lütgehetmann, Marc

    Published in JHEP reports (01-12-2021)
    “…Currently available HDV PCR assays are characterized by considerable run-to-run and inter-laboratory variability. Hence, we established a quantitative reverse…”
    Get full text
    Journal Article
  8. 8

    High Rates of Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic and Cardiovascular Comorbidities by Bockmann, Jan-Hendrik, Kohsar, Matin, Murray, John M, Hamed, Vanessa, Dandri, Maura, Lüth, Stefan, Lohse, Ansgar W, Schulze-Zur-Wiesch, Julian

    Published in Microorganisms (Basel) (30-04-2021)
    “…The prevalence of metabolic and cardiovascular diseases is rising worldwide. However, little is known about the impact of such disorders on hepatic disease…”
    Get full text
    Journal Article
  9. 9

    Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies by Allweiss, Lena, Volmari, Annika, Suri, Vithika, Wallin, Jeffrey J, Flaherty, John F, Manuilov, Dmitry, Downie, Bryan, Lütgehetmann, Marc, Bockmann, Jan-Hendrik, Urban, Stephan, Wedemeyer, Heiner, Dandri, Maura

    Published in Journal of hepatology (01-06-2024)
    “…Bulevirtide (BLV) is a first-in-class entry inhibitor and the only approved treatment for patients chronically infected with HDV in Europe. We aimed to…”
    Get full text
    Journal Article
  10. 10

    CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X by Karimova, Madina, Beschorner, Niklas, Dammermann, Werner, Chemnitz, Jan, Indenbirken, Daniela, Bockmann, Jan-Hendrik, Grundhoff, Adam, Lüth, Stefan, Buchholz, Frank, Wiesch, Julian Schulze zur, Hauber, Joachim

    Published in Scientific reports (03-09-2015)
    “…Current antiviral therapies cannot cure hepatitis B virus (HBV) infection; successful HBV eradication would require inactivation of the viral genome, which…”
    Get full text
    Journal Article
  11. 11
  12. 12

    Comparative Analysis of the Antiviral Effects Mediated by Type I and III Interferons in Hepatitis B Virus-Infected Hepatocytes by Bockmann, Jan-Hendrik, Stadler, Daniela, Xia, Yuchen, Ko, Chunkyu, Wettengel, Jochen M, Schulze Zur Wiesch, Julian, Dandri, Maura, Protzer, Ulrike

    Published in The Journal of infectious diseases (19-07-2019)
    “…Type III interferons (IFNs) (λ1-3) activate similar signaling cascades as type I IFNs (α and β) via different receptors. Since IFN-α and lymphotoxin-β activate…”
    Get full text
    Journal Article
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20